Serum 5-S-cysteinyldopa levels in patients with psoriasis undergoing narrowband ultraviolet B phototherapy

Clinical and Experimental Dermatology

Volumn 33, Issue 6, 2008, Pages 750-753

  Kikuchi, K ^a   Wakamatsu, K ^b   Tada, Y ^a   Komine, M ^a   Ito, S ^b   Tamaki, K ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b FUJITA HEALTH UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINYLDOPA; MELANIN; PHEOMELANIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; JAPANESE; MALE; MELANOMA; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS VULGARIS; RADIATION DOSE; REMISSION; TREATMENT DURATION; ULTRAVIOLET B RADIATION;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CYSTEINYLDOPA; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSORIASIS; SKIN; STATISTICS, NONPARAMETRIC; TIME; TREATMENT OUTCOME; ULTRAVIOLET THERAPY;

EID: 53349146008     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2008.02792.x     Document Type: Article

References (12)

1. Stierner U. Melanocytes, moles and melanoma - a study on UV effects. Acta Derm-Venereol Suppl 1991 168 : 1 31.
2. Dawe RS. A quantitative review of studies comparing the efficacy of narrow-band and broad-band ultraviolet B for psoriasis. Br J Dermatol 2003 149 : 669 72.
3. Scherschun L, Kim JJ, Lim HW. Narrow-band ultraviolet B is a useful and well-tolerated treatment of vitiligo. J Am Acad Dermatol 2001 44 : 999 1003.
4. Hansson C, Rorsman H, Rosengren E, Tegner T. 5-S-Cysteinyldopa and dopa in serum during treatment with 8-methoxypsoralen and UVA light. Acta Derm Venereol 1981 61 : 251 5.
5. Ito S. A chemist's view of melanogenesis. Pigment Cell Res 2003 16 : 230 6.
6. Wakamatsu K, Ito S, Fujita K. Production, circulation, and excretion of melanin-related metabolites in B16 melanoma-bearing mice. Acta Derm Venereol 1990 70 : 367 72.
7. Wakamatsu K, Kageshita T, Furue M et al. Evaluation of 5-S-cysteinyldopa as a marker of melanoma progression: 10 yrs' experience. Melanoma Res 2002 12 : 245 53.
8. Nimmo JE, Gawkrodger DJ, O'Docherty CSJ et al. Plasma 5-S-cysteinyldopa as an index of melanogenesis. Br J Dermatol 1988 118 : 487 96.
9. Wakamatsu K, Ito S. Evaluation of melanin-related metabolites as markers of solar ultraviolet-B radiation. Pigment Cell Res 2006 19 : 460 4.
10. Wakamatsu K, Ito S, Horikoshi T. Normal values of urinary excretion and serum concentration of 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2- carboxylic acid, biochemical markers of melanoma progression. Melanoma Res 1991 1 : 141 7.
11. Wakamatsu K, Ito S. Improved HPLC determination of 5-S-cysteinyldopa in serum. Clin Chem 1994 40 : 495 6.
12. Tegner E, Rorsman H, Rosengren E. 5-S-Cysteinyldopa and pigment response to UVA light. Acta Derm-Venereol 1983 63 : 21 5.